EnsoData uses Artificial Intelligence (AI) to unlock more rapid, accurate, and affordable diagnoses of the biggest threats to human health. With over eight years of pioneering clinical use and adoption of AI and machine learning technology in sleep medicine and broader healthcare, EnsoData tackles large-scale problems at the core of diagnosis and treatment decision-making.

The company's flagship solution, EnsoSleep, received FDA clearance in 2017 for diagnostic analysis of in-lab sleep studies and expanded clearance in 2021 to include home sleep studies analysis, viewing, editing, reporting, and total sleep time measurement. The latest FDA-cleared AI algorithm, EnsoSleep PPG, launched in 2024, transforms widely available pulse oximetry technology into a powerful diagnostic tool.

EnsoData aims to empower clinicians by reducing healthcare turnaround times, alleviating patient backlogs, and improving patient care and health outcomes. Their AI-driven tools provide clinicians with more opportunities to expand patient care, improve outcomes, reach more patients, and support sleep center growth.

EnsoData's technology harnesses waveform data to diagnose, monitor, and manage non-malignant, acute, and chronic conditions such as heart disease, diabetes, mental health, seizure disorders, Alzheimer's, Parkinson's, dementia, aging, stroke, and more.